Day One Biopharmaceuticals, Inc. (DAWN) reported Q4 Revenue ; Offers Guidance
Tweet
Share
E-mailGet Alerts DAWN Hot Sheet
Join SI Premium – FREE
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) reported Q4 Revenue for the quarter came in at $52.8 million versus the consensus estimate of $45.86 million.
GUIDANCE:
Day One Biopharmaceuticals, Inc. sees FY2026 revenue of $225-250 million, versus the consensus of $236.6 million.
For earnings history and earnings-related data on Day One Biopharmaceuticals, Inc. (DAWN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) PT Lowered to $92 at Mizuho
- Toro Company (TTC) Tops Q3 EPS by 3c; offers guidance
- Samsara hits $2.1B in ARR with 30% year-over-year growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
